Publications

Learn about the research supporting our preclinical and clinical development programs.

Publications

May 12, 2020
Molecular Cancer Therapeutics

MMAE delivery using the Bicycle toxin conjugate BT5528

March 30, 2020
Journal of Medicinal Chemistry

Identification and Optimization of EphA2-Selective Bicycles for Delivery of Cytotoxic Payloads

February 15, 2019
AACR Journals

Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors

June 6, 2018
ADMET

Application of biomimetic HPLC to estimate lipophilicity, protein and phospholipid binding of potential peptide therapeutics

March 8, 2018
Journal of Medicinal Chemistry

Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema

July 1, 2012
ChemMedChem

Bicyclic Peptides with Optimized Ring Size Inhibit Human Plasma Kallikrein and its Orthologues While Sparing Paralogous Proteases

May 31, 2009
Nature Chem Bio

Phage-encoded combinatorial chemical libraries based on bicyclic peptides

Presentations

AACR

June 22, 2020
A survey of EphA2 expression by immunohistochemistry (IHC) in tumor tissue microarrays (TMAs) to support BT5528 indication selection

June 22, 2020
A novel fully synthetic dual targeted EphA2/CD137 Bicycle® peptide induces tumor localized CD137 agonist

June 22, 2020
BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized CD137 agonist

ASCO

May 29, 2020
BT5528-100 phase I/II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients with advanced malignancies associated with EphA2 expression.

2019

2018

2017